Impact of Anesthesia Type on Outcomes of Transcatheter Aortic Valve Implantation (from the Multicenter ADVANCE Study). by Brecker, SJ et al.
1 
 
 
 
Impact of Anesthesia Type on Outcomes of Transcatheter Aortic Valve Implantation From 
the Multicenter ADVANCE Study 
 
Stephen J.D. Brecker,a* MD, Sabine Bleiziffer,b MD, Johan Bosmans,c MD, PhD, Ulrich 
Gerckens,d MD, Corrado Tamburino,e MD, Peter Wenaweser,f MD, and Axel Linke,g MD, for 
the ADVANCE Study Investigators 
 
Department and Institutions: aSt. George’s Hospital, London, United Kingdom; bGerman 
Heart Centre, Technical University Munich, Germany; cUniversity Hospital Antwerp, 
Belgium; dGemeinschaftskrankenhaus, Bonn, Germany; eFerrarotto Hospital, University of 
Catania, Italy; fBern University Hospital, Switzerland; gUniversity of Leipzig Heart Centre, 
Germany 
 
Short Running Title: Anesthesia Use in CoreValve ADVANCE  
 
ClinicalTrials.gov Identifier: NCT01074658 
 
 
*Correspondence to:  
 
Stephen J.D. Brecker, MD, Chief of Cardiology, St. George's Hospital, Blackshaw Road, 
London SW170QT, United Kingdom. Telephone +44-(0)20-8725-3556. Fax +44-(0)20-
8725-0322. E-mail: sbrecker@sgul.ac.uk 
 
  
2 
 
 
 
ABSTRACT 
Transcatheter aortic valve implantation (TAVI) has become the standard of care for many 
patients with symptomatic severe aortic stenosis who are at increased risk of morbidity 
and mortality during surgical aortic valve replacement. However, there is still no general 
consensus regarding the use of general anesthesia (GA) versus local anesthesia with 
sedation (non-GA) during the TAVI procedure. Using propensity score matching analysis, 
we analyzed the characteristics and outcomes of patients undergoing TAVI with either GA 
(n=245) or non-GA (n=245) in the fully monitored, international, CoreValve ADVANCE 
Study. No statistically significant differences existed between the non-GA and GA groups in 
all-cause mortality (25.4% vs. 23.9%, p=0.78), cardiovascular mortality (16.4% vs. 16.6%, 
p=0.92), or stroke (5.2% vs. 6.9%, p=0.57) through 2-year follow up. Major vascular 
complications were more common in the non-GA group. Total hospital stay was similar 
between the 2 groups. Conversion from non-GA to GA occurred in 13 patients (5.3%) due 
to procedural complications in 9 patients and discomfort or restlessness in 4 patients. The 
majority of the procedural complications were related to valve positioning or vascular 
issues. Two of the 13 converted patients died during the procedure. Both GA and non-GA 
are widely used in real-world TAVI practice, and the decision appears to be guided by only 
a few patient-related factors and dominated by local and national practice. The outcomes of 
both anesthesia modes are equally good. When conversion from non-GA did occur, the 
complication requiring GA affected outcomes. 
 
Key words: severe aortic stenosis, transcatheter aortic valve replacement; anesthesia; 
real-world clinical trial  
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Transcatheter aortic valve implantation (TAVI) has become standard of care for patients 
with symptomatic severe aortic stenosis at extreme or high risk for surgery.1 In practice, 
even lower risk patients are already being treated, while at least 3 TAVI clinical trials are 
assessing the role of the therapy in patients considered at only intermediate risk from 
surgical AVR. It is therefore likely the number of patients treated with TAVI will increase, 
requiring additional numbers of operators and hospitals. Concurrently, the procedure is 
becoming less complex. Smaller sheath sizes, a reduced need for rapid pacing and balloon 
valvuloplasty, availability of repositionable and recapturable valves, and decreased 
reliance upon intraprocedural transesophageal echocardiography will herald a new era of 
TAVI. A significant proportion of procedures are already being performed using local 
anesthesia with sedation. Others have reported potential benefits of using local anesthesia, 
including shorter intensive care unit and overall hospital stays, less hemodynamic 
instability, and less need for vasopressors.2-5 It is likely that the proportion of patients 
treated in this manner will increase.  In the ADVANCE study6, patients were treated 
according to best local practice in experienced centers, and a significant proportion was 
treated with local rather than general anesthesia. Local anesthesia was used in 
approximately 50% of patients in this study, reflecting the real-world practice at the time, 
and we compared patient characteristics and procedural outcomes in patients 
administered local versus general anesthesia for TAVI. 
 
Methods 
For this report, we analyzed the characteristics and outcomes of patients 
undergoing TAVI with either general anesthesia (GA) or local anesthesia with sedation 
4 
 
 
 
(non-GA) in the Medtronic CoreValve ADVANCE study.  Patients treated via the direct aortic 
approach were excluded from this analysis. The design, methods, and primary results of 
the ADVANCE study have been previously described.6 Briefly, the ADVANCE study is a 
prospective, fully monitored, nonrandomized, international, multicenter study evaluating 
the acute and long-term results of implantation of the Medtronic CoreValve System 
(Medtronic, Minneapolis, Minnesota) in “real-world” patients with severe, symptomatic 
aortic stenosis who were considered to have an inoperable condition or to be at high risk 
for conventional AVR. All ADVANCE study centers were required to have performed a 
minimum of 40 TAVI procedures prior to joining the study and to utilize an on-site, 
multidisciplinary Heart Team consisting of at least 1 TAVI-experienced interventional 
cardiologist and 1 cardiovascular surgeon.  
The ethics committee at each study center approved the ADVANCE investigational 
protocol. ADVANCE was conducted in adherence to the Declaration of Helsinki, and all 
patients provided written informed consent prior to the CoreValve implantation procedure.  
Detailed device description and implant procedures for the CoreValve System have 
been previously described.7,8 The procedures were performed according to standard local 
hospital practices, which included the selection of access location (transfemoral,  or 
subclavian), the type of access (surgical cutdown or completely percutaneous), and the 
type of anesthesia (GA or non-GA). Procedural characteristics analyzed for the comparisons 
between anesthesia groups included access type and site, procedure duration, fluoroscopy 
time, quantity of contrast agent used, procedural complications, and length and type of 
hospital stay.  
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Safety outcomes were analyzed at 30 days and at 1 and 2 years post-procedure and 
included all-cause mortality, cardiovascular mortality, myocardial infarction, 
reintervention, stroke, stroke or transient ischemic attack, bleeding, vascular 
complications, acute kidney injury (stage III), and pacemaker implantation. 
Death, stroke, myocardial infarction, and reintervention were adjudicated by an 
independent Clinical Events Committee consisting of TAVI-experienced interventional 
cardiologists and a cardiac surgeon using the initial Valve Academic Research Consortium 
definitions.9 An independent neurologist reviewed the neurological events and provided a 
summary of each event to the Clinical Events Committee, which used this information along 
with any other patient source data to adjudicate all neurological events. A core laboratory 
(Cardialysis, Rotterdam, The Netherlands) performed a systematic review and assessment 
of procedural angiograms and ECGs through 1-year follow-up. Data were recorded on a 
standardized electronic case report form and sent to a central database (Merge, Chicago, 
Illinois) over the Internet. 
Categorical variables are reported as counts and percentages. Continuous variables 
are reported as means and standard deviations except for non-normal data such as logistic 
EuroSCORE, Society of Thoracic Surgeons (STS) predictive risk of mortality score, 
procedure duration, fluoroscopy time, amount of contrast given, and length of stay, which 
are summarized using medians and interquartile ranges. 
Comparisons between anesthesia types are based on chi-square or Fisher’s exact 
tests for categorical variables, and t-tests or Wilcoxon tests for continuous variables, as 
appropriate. Event rates were generated using the Kaplan-Meier method, and log-rank 
tests were used for group comparisons. For patients without an event, the date of censoring 
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was the latest date of all follow-up visits (including study exit) and events (including 
death). A p value < 0.05 was considered statistically significant. 
To identify 2 comparable groups of patients undergoing GA or non-GA, we 
performed a propensity score matching analysis. A multivariable logistic regression model 
with anesthesia type as the outcome was fit, from which predicted probabilities (i.e., 
propensity scores) were computed for each patient. Unbalanced variables prior to 
matching as well as an additional 10 variables were included in the model to achieve 
balance in baseline characteristics in the anesthesia groups after matching. The baseline 
covariates included in the model were female, New York Heart Association class III or IV, 
diabetes mellitus, previous median sternotomy, previous aortic valve intervention, prior 
coronary artery bypass grafting, history of aortic aneurysm, creatinine clearance < 20 
mL/min,  baseline left ventricular ejection fraction, moderate or severe tricuspid 
regurgitation, log transformed age, square root transformed EuroSCORE, history of 
myocardial infarction,  peripheral vascular disease, baseline pacemaker,  cerebrovascular 
disease, and  atrial fibrillation. Characteristics were considered to be in balance if the 
percent standardized difference was < 10%. All statistical analyses were performed using 
SAS software (version 9.3; SAS Institute, Inc., Cary, North Carolina). 
 
Results 
From March 2010 to July 2011, 1,015 patients were enrolled in the ADVANCE study. 
Of these, 996 patients had undergone an attempted implantation with the CoreValve 
System. The mode of anesthesia was entirely site-selected and guided by best and 
customary local practice. Considering the whole group of patients, non-GA was used in 551 
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(55.3%) patients, and GA was used in 445 (44.7%) patients. Twenty-one patients treated 
via the direct aortic access were omitted as they are not considered candidates for both 
anesthesia options, leaving 424 patients in the GA group. Baseline patient characteristics 
are presented in Table 1. Significant differences existed between the 2 patient groups in 
diabetes, previous median sternotomy, previous aortic valve intervention, previous 
coronary artery bypass grafting and left ventricular ejection fraction. Despite these 
differences, the median STS predictive risk of mortality score and logistic were similar 
between the 2 groups. There were national differences in the use of non-GA versus GA (Fig. 
1), demonstrated by large differences in the use of non-GA among the highest recruiting 
countries (Germany, 78.6%; Italy, 70.5%; and the United Kingdom, 4.6%). 
Since several statistically significant differences in baseline patient characteristics 
existed between the GA and non-GA groups which could have potentially affected the 
results of the analysis, we performed a propensity-score matched analysis. A standardized 
difference of 10% was used as the basis for defining successful matching, where a lower 
standardized difference corresponds to higher degree of achieved balance. Propensity 
scoring resulted in 245 matched pairs of patients (Table 1). All of the following outcomes 
analyses are based on these 2 propensity matched anesthesia groups. 
Procedural characteristics and outcomes are listed in Table 2. The vast majority of 
cases were performed transfemorally. Patients treated using GA had significantly longer 
median procedure and fluoroscopy times. More patients implanted via the percutaneous 
approach were treated with non-GA compared with GA, whereas more patients who had 
surgical cutdown were treated with GA (Table 2). Thus, the method of access may have 
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affected choice of anesthesia. No statistically significant differences were seen in 
procedural complications. Total hospital stay was similar between the groups. 
 Conversion from non-GA to GA occurred in 13 patients during their procedure. A 
total of 20 procedural complications occurred in 9 of the 13 patients. The remaining 4 
converted patients did not experience a procedural complication and thus were most likely 
converted to GA because of discomfort or restlessness. The majority of the procedural 
complications were related to valve positioning or vascular issues.  The valve was 
repositioned with snare or retrieved in 3 patients; failure of the vessel closure device 
requiring surgery occurred in 3 patients; access vessel occlusion (treated with 
percutaneous balloon) occurred in 1 patient, access vessel perforation (required 
transfusion) occurred in 1 patient, and 1 patient experienced hemorrhage requiring 
transfusion and cardiorespiratory arrest. Two of the 13 converted patients died during the 
TAVI procedure.  
Safety outcomes at 30 days and at 1 and 2 years are presented in Table 3. All-cause 
mortality (Fig. 2), cardiovascular mortality, and stroke were similar between the non-GA 
and GA patients through 2 years of follow-up. However, non-GA patients had significantly 
higher incidence of major vascular complications at all time points. 
 
Discussion 
In the present study we compared the characteristics and outcome of patients 
undergoing TAVI with GA versus non-GA. Before discussing the issues identified in this 
study, it is worth considering the terminology used in previous studies. First, GA is defined 
by the patient having been placed in a state of “unconsciousness” such that they are 
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unaware of their physical state and are unable to communicate. Typically this will involve 
the administration of either inhalational or intravenous anesthetic agents, paralyzing 
agents, insertion of an endotracheal tube, and artificial ventilation. The terminology of 
anything that is not general anesthesia (non-GA) is confusing, as evidenced by the wide 
range of descriptions in the literature. These include “local anesthesia,” “regional 
anesthesia,” “conscious sedation,” “light sedation,” “deep sedation,” and “controlled 
monitored anesthesia.” There are 2 components to any non-GA approach. The first 
component is the relief of pain, and this is administered by true local anesthesia, typically 
with lidocaine, or with regional or epidural anesthesia. The second component is sedation, 
and this can range from very mild sedation, where the patient is able to communicate, to 
deeper sedation, where they cannot. Most anesthesiologists would consider deep sedation 
a form of GA but without protection of the airway. 
Previous studies have suggested potential advantages of a non-GA procedure, 
including shorter procedure times, shorter intensive care unit and overall hospital stays, 
lower vasopressor requirements, and equally good outcomes in terms of mortality.2-5 
Others have identified that a non-GA approach may require conversion to GA in up to 5% of 
cases for cardiac arrest, tamponade, myocardial infarction, or procedural stroke.10 A higher 
incidence of paravalvular regurgitation has been recorded in 1 study of patients treated 
with non-GA, perhaps reflecting a reluctance of operators to prolong the procedure to 
undertake further post-deployment valvuloplasty or second valve deployment.11 
In this study we did not prospectively define GA or non-GA, nor was the study 
randomized; instead, it reflected real-world practice. In the ADVANCE study, the choice of 
anesthetic and mode of local anesthesia was dependent upon local practice, and this varied 
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among both hospitals and countries (Fig. 1). It therefore seems that local trends, both 
within a hospital and within a country, may define the popularity of using local versus 
general anesthesia.12 There are numerous factors that influence the decision, including 
patient-related factors, but more often than not it would appear that the factors 
determining which type of anesthesia is used are operational and logistic as overall risk 
scores between the 2 groups were no different. 
In our study the baseline patient characteristics between the 2 groups were similar, 
but some important differences were observed. To account for these differences, we 
carried out a propensity score matched analysis. In terms of overall outcomes between the 
propensity score matched groups, non-GA procedures were 18 minutes shorter, less than 
recently reported from a similarly sized cohort.13 The only other significant difference was 
a higher preponderance of major vascular complications, and there was a trend toward a 
higher number of patients receiving pacemakers at 30 days in the non-GA group. This 
might possibly be explained by a greater enthusiasm for attempted repositioning of a 
deeply implanted valve in a patient under GA.  Apart from these, there were no significant 
differences in the very low incidence of procedural complications or in intensive care unit 
stay. Furthermore, outcomes (i.e., mortality and major adverse cardiac and cerebrovascular 
events) in the non-GA and GA groups were similar at 30 days, 1 year, and 2 years. Major 
vascular complications occurred more often in the non-GA group, probably reflecting a 
higher incidence of surgical cutdown as the initial strategy, whereas conversion to cutdown 
in the non-GA group was considered a major vascular complication.  
While overall outcomes were broadly similar between the 2 groups on an “intention 
to anesthetize” basis, there was an important subset of patients who converted from non-
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GA to GA during the procedure. The rate of conversion in this study was 5.3%, and this is 
similar to other studies.4,10,13 The reasons for conversion in this study were predominantly  
related to valve positioning issues and vascular complications requiring surgery. It is no 
surprise, therefore, that the need for conversion is actually a surrogate for procedural 
complications, and the outcomes reflect this. That is not to say that non-GA is not safe—as 
we have demonstrated, it is. However, it is important to recognize that the need to convert 
to GA reflects complications that could have occurred in the GA group as well, but would 
not have mandated any change in anesthesia type. 
Limitations associated with this study were that we did not prospectively define GA 
or non-GA, nor did we require sites to supply specific anesthetic details or the specific 
reason for conversion. The study was non-randomized, and we relied upon the sites to use 
best and customary local practice to guide the choice of anesthesia mode, but we did not 
collect the specifics of the rationale.  Our propensity-score matched analysis did however 
remove the potential confounding influence of baseline characteristics. 
Both GA and non-GA are widely used in real-world TAVI practice, and the decision 
appears to be guided by only a few patient-related factors and dominated by local and 
national practice. The outcomes of both modes are equally good, and the need for 
conversion from non-GA to GA was 5.3% in this study. When conversion did occur, the 
complication requiring GA affected outcome. 
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FIGURE LEGENDS 
Fig. 1. The distribution of the use of general anesthesia (GA), local anesthesia (non-GA), 
and changed (non-GA to GA) by country for all patients. The number of centers per country 
and the number of patients enrolled are shown.  
 
Fig. 2. Kaplan-Meier analysis of all-cause mortality through 2 years by propensity matched 
anesthesia groups. GA, general anesthesia; Non-GA, local anesthesia. 
 
